IMIDomics Inc. Secures Exclusive Worldwide Licensing Agreement with TNAX Biopharma Corporation for TNAX101A (IMB1001), A Promising Drug Candidate for Immune-Mediated Inflammatory Diseases

SAN RAFAEL, Calif.–(BUSINESS WIRE)–IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced an exclusive license agreement with TNAX Biopharma Corporation (TNAX), an innovator in biotechnology. Under this agreement, TNAX is granting IMIDomics the worldwide rights to develop, manufacture, commercialize and sublicense IMB1001,…
Click here to view original post